EU Authorized Representative for Medical Devices and IVDs in Europe
For non-EU manufacturers, placing medical devices or in vitro diagnostic devices in Europe requires more than product quality, technical files and regulatory planning. Before a device can be placed on the European market, the manufacturer must appoint an EU Authorized Representative who is physically located in the European Union and legally recognised as the manufacturer’s official representative. This function is critical under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation as regulators require a responsible local entity to manage communication, supply documentation and assist with compliance obligations when needed. An eu-authorized-representative is not simply a name on a label. The representative acts as the legal presence of a non-EU manufacturer and plays an important role in maintaining market access, regulatory confidence and post-market accountability.
Why an EU Authorized Representative Is Required
European medical device rules are designed to protect patients, healthcare professionals and users by ensuring that every product placed on the market has a clear chain of responsibility. If a manufacturer operates outside the European Union, regulators cannot always interact with them as easily as they would with a locally established company. This is where the EU Authorized Representative becomes necessary. The representative provides a formal local presence and serves as the official point of communication for Competent Authorities, Notified Bodies and other regulatory stakeholders.
Without appointing an authorised representative, a non-EU manufacturer cannot legally place medical devices or IVDs on the European market. This applies to a wide range of products, from simple low-risk devices to complex diagnostic technologies. This obligation applies before market entry, meaning the representative must be selected early in the compliance journey rather than as a last administrative step. For manufacturers planning European distribution, choosing the right EU Authorized Representative for Medical Devices and IVDs can directly affect registration readiness, documentation control and long-term regulatory stability.
The Written Mandate Between Manufacturer and Representative
The connection between the manufacturer and the EU Authorized Representative must be formalised through a written mandate. This document outlines the activities the representative is permitted to carry out and confirms the responsibilities of both parties. It is a critical compliance record as it defines the scope of representation, responsibilities, communication roles and the actions required if compliance issues occur.
A vague or poorly prepared mandate can create uncertainty at the worst possible time, especially during an authority request, inspection, complaint review or corrective action. A robust mandate should clearly explain document availability, regulatory communication procedures, incident reporting processes and the steps taken if the manufacturer fails to meet obligations. Therefore, the mandate must be carefully drafted and reviewed before registration or market entry begins.
Label and Packaging Requirements
The name and address of the EU Authorized Representative must be displayed on the device label, packaging or associated product information in accordance with applicable regulations. This allows authorities, distributors, healthcare professionals and users to identify the local representative linked to the device. It also reinforces the representative’s role as the official European presence for a manufacturer located outside the European Union.
Labelling accuracy matters because incorrect or missing representative information can create compliance concerns and may delay market access. Manufacturers should ensure that their artwork, instructions, declarations and registration information are aligned before products are released. If the representative is changed, labelling and registration details may also require timely and controlled updates.
Documentation Review and Availability
A key responsibility of an EU Authorized Representative for Medical Devices and IVDs is to ensure that essential compliance documents are available and correctly prepared. This involves confirming the existence of the EU Declaration of Conformity, ensuring technical documentation is complete and verifying that the appropriate conformity assessment route has been followed based on device type and risk classification.
The representative may also need to hold or have access to copies of technical documentation, declarations and Notified Body certificates. These records must remain accessible for inspection by Competent Authorities for the specified retention period after the last device is marketed. This makes document control a central part of the relationship between manufacturer and representative. Manufacturers should keep records updated and ensure the representative can respond promptly to regulatory requests.
Communication With Competent Authorities and Notified Bodies
The EU Authorized Representative serves as the formal communication link between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response process. The representative may also liaise with Notified Bodies when necessary, particularly regarding certification, conformity assessments or corrective measures.
This communication function goes beyond simply passing messages. A reliable representative should understand regulatory expectations, keep accurate records and ensure that requests are handled within appropriate timelines. Late or incomplete replies can lead to serious consequences, including market limitations or additional regulatory scrutiny. Therefore, manufacturers should partner with a representative who has strong regulatory expertise and well-defined internal systems.
Post-Market Surveillance and Incident Support
Medical device compliance does not end after market entry. Once a device is in use, manufacturers must continue monitoring performance, complaints, incidents and safety signals. The EU Authorized Representative supports this post-market obligation by promptly forwarding complaints and incident reports to the manufacturer.
This is particularly critical when information originates from clinicians, patients, users, distributors or authorities. Timely communication helps the manufacturer assess whether further investigation, reporting, field safety action or corrective action is needed. A strong representative understands that post-market surveillance is not just paperwork. It is part of patient safety, product improvement and ongoing regulatory trust.
Registration Responsibilities and EUDAMED
Under European regulatory systems, manufacturer and representative details must be registered as required. The EU Authorized Representative may support the registration of both the manufacturer and representative information in EUDAMED. Accurate registration helps authorities identify responsible parties, review device information and maintain market oversight.
Manufacturers should prepare complete company details, device information, certificates and declarations before registration activities begin. Any mismatch between labelling, declarations, technical documentation and registration records may lead to delays or compliance concerns. The representative’s role helps ensure all required information is aligned and accessible when required.
When the Representative Must Take Action
An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If significant non-compliance arises and is not corrected by the manufacturer, the representative may need to terminate the mandate and notify relevant authorities and the Notified Body where relevant. This responsibility shows why the role is more than administrative.
The representative has legal accountability and cannot ignore major compliance failures. Manufacturers should therefore view the representative as a regulatory partner rather than a passive provider. Clear communication, regular document updates and defined responsibilities help avoid misunderstandings and minimise risk throughout the product lifecycle.
Choosing the Right EU Authorized Representative
Selecting an EU Authorized Representative should be done with care. Manufacturers should evaluate regulatory expertise, experience in medical devices and IVDs, document management capabilities, clear response processes and strong knowledge of European regulations. The representative should effectively handle authority communication, maintain records and guide the manufacturer on practical compliance matters.
Cost alone should not determine the choice. An ineffective representative may lead to delays, communication gaps and increased eu-authorized-representative risk, whereas a strong representative can support confidence during market entry and beyond. The right choice gives non-EU manufacturers a dependable European presence and supports smoother regulatory management.
Conclusion
An EU Authorized Representative is essential for non-EU manufacturers that want to place medical devices or IVDs on the European market. The role includes legal representation, documentation availability, authority communication, complaint handling, registration support and action in cases of serious non-compliance. Under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is mandatory and must be done before market entry. By choosing a competent EU Authorized Representative for Medical Devices and IVDs, manufacturers can strengthen compliance, support patient safety and build a reliable foundation for long-term access to the European market.